The gross proceeds from the offering to Acadia, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Acadia, are approximately USD 316.2m.
BofA Merrill Lynch, J.P. Morgan Securities LLC and Goldman Sachs and Co. LLC acted as the joint book-running managers for the offering.
Cowen and company, LLC acted as lead manager and Cantor Fitzgerald and Co., JMP Securities LLC and Needham and Company, LLC acted as co-managers for the offering.
Acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.
The company has developed and is commercializing the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
In addition, Acadia has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder, and Rett syndrome.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials